Bronchitis - Pipeline Review, H1 2018

  • ID: 4482734
  • Report
  • 68 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Han Wha Pharma Co Ltd
  • Icure Pharmaceutical Inc
  • Merck & Co Inc
  • MORE
Bronchitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Bronchitis - Pipeline Review, H1 2018, provides an overview of the Bronchitis (Respiratory) pipeline landscape.

Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked, shortness of breath aggravated by exertion or mild activity, frequent respiratory infections that worsen symptom, wheezing, fatigue, ankle that affects both sides and headaches. Risk factors include smoking, low resistance and gastric reflux.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Bronchitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bronchitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 3, 3 and 1 respectively.

Bronchitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchitis (Respiratory)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Han Wha Pharma Co Ltd
  • Icure Pharmaceutical Inc
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

Bronchitis - Overview

Bronchitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchitis - Companies Involved in Therapeutics Development

Advanced Inhalation Therapies (AIT) Ltd

AstraZeneca Plc

DBV Technologies SA

F. Hoffmann-La Roche Ltd

Han Wha Pharma Co Ltd

Icure Pharmaceutical Inc

Kyorin Pharmaceutical Co Ltd

Merck & Co Inc

Mucosis BV (Inactive)

Orbis Biosciences Inc

Therabron Therapeutics Inc

Bronchitis - Drug Profiles

alteplase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alvelestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

formoterol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lascufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirfenidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prednisone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YJP-40 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchitis - Dormant Projects

Bronchitis - Discontinued Products

Bronchitis - Product Development Milestones

Featured News & Press Releases

Jan 23, 2017: Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets

Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings

Feb 03, 2014: AIT to Present Noxcurebr at the Annual Meeting Of The Israeli Association Of Clinical Pediatrics

Jan 19, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants

Jan 15, 2013: DBV Technologies and INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bronchitis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bronchitis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2018

Bronchitis - Pipeline by AstraZeneca Plc, H1 2018

Bronchitis - Pipeline by DBV Technologies SA, H1 2018

Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Bronchitis - Pipeline by Han Wha Pharma Co Ltd, H1 2018

Bronchitis - Pipeline by Icure Pharmaceutical Inc, H1 2018

Bronchitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Bronchitis - Pipeline by Merck & Co Inc, H1 2018

Bronchitis - Pipeline by Mucosis BV (Inactive), H1 2018

Bronchitis - Pipeline by Orbis Biosciences Inc, H1 2018

Bronchitis - Pipeline by Therabron Therapeutics Inc, H1 2018

Bronchitis - Dormant Projects, H1 2018

Bronchitis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Bronchitis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Bronchitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advanced Inhalation Therapies (AIT) Ltd
  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Han Wha Pharma Co Ltd
  • Icure Pharmaceutical Inc
  • Kyorin Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Mucosis BV (Inactive)
  • Orbis Biosciences Inc
  • Therabron Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll